Avicanna's Groundbreaking Export of CBD Cannabis Flower
Avicanna Inc. (TSX: AVCN) is thrilled to announce a significant milestone in its expansion strategy with the completion of its first export of non-psychoactive CBD dominant cannabis flower into Switzerland. This remarkable achievement was made possible through its majority-owned subsidiary, Santa Marta Golden Hemp SAS (SMGH), which has paved the way for Avicanna into new international markets.
The Impact of This Export
This export of CBD flower marks the 20th international market for the company's Aureus branded products and the 23rd overall for Avicanna. This accomplishment demonstrates the company's dedication and capability in navigating complex regulations to ensure successful market entry. The launch of this export comes after significant improvements in 2024, where Avicanna focused on optimizing internal practices and enhancing the local infrastructure at SMGH.
Expanding Product Offerings
Avicanna is continually striving to meet the growing demand for medical cannabis flower in Europe and Australia. By providing a diverse range of proprietary and premium CBD, CBG, and THC genetics, the company is well-positioned to cater to the evolving needs of medical markets. The shipment included three unique proprietary varieties from Avicanna's registered portfolio in Colombia.
About the Aureus™ Brand
The Aureus™ brand represents Avicanna's commitment to quality and innovation in the cannabinoid market. It includes raw materials and active pharmaceutical ingredients (API) produced through SMGH. These high-quality cannabis raw materials are integral to Avicanna's global supply chain, supporting their medical cannabis and consumer retail products.
Commitment to Quality and Compliance
SMGH is dedicated to maintaining high standards of quality and sustainability. The facility has received both Good Agricultural and Collection Practices (GACP) and Organic certifications, which are recognized under the USDA National Organic Program. With an impressive cultivation space of approximately 300,000 square feet and an extraction capacity of 300kg, the facility currently yields around 26,400 kg of product annually.
Avicanna's Vision and Future Initiatives
Avicanna is not just focused on immediate opportunities; the company has a well-defined vision for its role in the global biopharmaceutical market. With a robust platform for research and development, Avicanna is engaged in commercializing over thirty proprietary, evidence-based formulations catering to various medical needs.
Diverse Offerings in the Medical Sector
The company's product lineup includes the RHO Phyto™ medical cannabis formulary, which features a variety of cannabinoid formulations across multiple delivery methods. With ongoing education for healthcare professionals and patients alike, RHO Phyto™ is already a notable presence in the Canadian market. Additionally, the MyMedi.ca platform aims to enhance the patient experience through tailored support and resources.
Pipeline and Active Ingredients
Avicanna's pharmaceutical pipeline is a testament to its commitment to innovation. The company is developing proprietary cannabinoid-based candidates aimed at addressing complex health issues like chronic pain and dermatological conditions. These developments showcase Avicanna's understanding of market needs and its dedication to improving patient outcomes through science-backed products.
Global Network and Collaboration
SMGH also plays a crucial role in supplying various forms of CBD, THC, and CBG to international partners, creating a strong network of collaboration across industries. This alignment with partners enhances Avicanna's potential to thrive in various sectors while producing quality medical, consumer and pharmaceutical products.
Conclusion
Overall, Avicanna's recent export to Switzerland is a landmark achievement that reflects its operational fortitude and strategic growth objectives. The company’s focus on quality, compliance, and international market expansion strengthens its position as a leader in the biopharmaceutical field. As Avicanna continues to evolve, its commitment to advancing cannabinoid-based therapies will undoubtedly play a significant role in shaping the future of medical cannabis.
Frequently Asked Questions
What does Avicanna specialize in?
Avicanna specializes in the development and commercialization of plant-derived cannabinoid-based products for medical and pharmaceutical markets.
What is the significance of the export to Switzerland?
The export to Switzerland is Avicanna's first of CBD dominant cannabis flower, marking a milestone in their international growth strategy.
What certifications does SMGH have?
SMGH holds Good Agricultural, and Collection Practices (GACP) and Organic certifications under the USDA National Organic Program.
What products does the Aureus™ brand offer?
Aureus™ offers raw materials and APIs, including various forms of CBD, CBG, and THC, produced through SMGH.
How does Avicanna ensure product quality?
Avicanna ensures product quality through stringent compliance with laws and regulations, maintaining high manufacturing standards in all operations.
